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Abstract:  
Global Value Chains and Smart Specialisation Strategy 
The paper elaborates the foundations and functioning of global value chains, the importance of their analysis 
within the S3 context, in line with the existing RIS3 framework. A methodological approach to analysing a 
country’s position in GVCs in terms of activities, flows and relationships is presented. The approach is illustrated 
with its application to the Irish pharmaceutical sector. 
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Executive summary 
Policy context 
This brief has considered GVCs within the context of smart specialisation. A 
methodological approach has been described that analyses a country’s (region’s) 
position in GVCs. This approach has been applied to the case of the pharmaceutical 
industry in Ireland.  
A similar approach can be applied to other locations pertaining to that industry or other 
industries. By doing so, the comparative advantage of the industry can be assessed and 
its degree of participation in the industry GVC can be assessed including establishing 
those locations that serve as its main sources of inputs and destinations of its outputs. 
Thus the linkages of the industry and their extent can be established.  
At the same time, the analysis can reveal where along the value chain the industry is 
positioned and the extent of that positioning. Thus the analysis points to opportunities 
for maintaining/extending/deepening the country’s positioning on the GVC. Furthermore, 
by applying a similar analysis to other locations, a location can ascertain who else 
occupies significant parts of the industry value chain, and how strong their positions are 
and whether those clusters of GVC activities in these other competing regions/countries 
are similar/complementary to their own activities. Taking account of the previously 
identified linkages, this can indicate whether there might be opportunities to capitalise 
on complementarities in other locations and the development of inter-regional/trans-
European linkages. To explore such opportunities requires engaging in the digging (D) 
stage of our MD3A process described in the brief. This implies a focus on the extant 
clusters of the industry GVC. 
Since the data required at the digging stage may be unavailable or indeed difficult to 
access, there is a need to identify conduits/boundary spanners who are connected to the 
industry and have a deep knowledge of the industry cluster and its characteristics. These 
conduits/boundary spanners are likely to be found within national and regional 
development agencies and/or enterprise development agencies. For each location, one 
such individual might be assigned an S3 responsibility within the context of the industry 
GVC. Platforms – real and virtual - would need to be developed to facilitate engagement 
among such conduits/boundary spanners so that opportunities for intra-regional industry 
GVC linkages can be precisely identified and pursued and that match-making takes 
place.  
Key conclusions 
This paper has highlighted a number of important matters in relation to GVCs and S3. 
These are considered from the specific context of the case of the Irish pharmaceutical 
industry and more generally from a methodological perspective. We can suggest some 
general principles that can be followed. These entail engaging with the Industry and its 
stakeholders on a continuous basis, anticipating the likely evolution of the Industry 
globally, assessing the challenges and opportunities that are likely to ensue from future 
industry trajectories, and responding to those challenges and opportunities in a proactive 
manner. 
This process of Engaging, Anticipating, Assessing and Responding (EAAR) is required to 
be followed on an on-going basis and must involve the active participation of all 
stakeholders. The on-going success of Ireland in the changing Pharmaceutical Industry is 
an instructive example of RIS3 in action from which specific lessons can also be 
observed: 
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I. The provision of a compatible and supportive environment via a relevant 
infrastructure that encompasses a robust regulatory framework, research and 
technology and education. 
II. The upgrading and sustaining of a national innovation system. 
III. The development of the requisite human capital pool.  
IV. The supporting and nurturing of collaboration among all stakeholders. 
V. The engagement in upgrading of existing activities in the industry and  
VI. The anticipating and targeting of areas of growth within the industry. 
Finally in relation to some methodological perspectives, we have already observed that 
the macro analysis (followed in the preceding section and applied to the Irish 
pharmaceutical industry) offers very useful insights into the industry within a GVC 
context. However, this represents one stage of the M3DA process outlined in Section 3 
viz. the mapping (M) stage. The subsequent stages of digging, determining, 
decomposing (3D) and ascertaining (A) call for micro level analyses. These are 
particularly important if regional authorities are to play a role in co-creating and 
developing European industrial value chains based on smart specialisation priorities. 
This calls for the interregional knowledge building, mapping the matchmaking potential 
around GVCs between regional smart specialisation priorities, identifying some pilot 
examples of interregional value chains, key stakeholders, available equipment and 
facilities and relevant actors/skills in smart specialisation areas and applying the 
methodology described above with a view to identifying opportunities for matching of 
national and regional cluster organisations in identified value chains of smart 
specialisation areas. 
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1. Introduction 
The Smart Specialisation principle, which was initially defined by the ‘Knowledge for 
Growth’ Expert Group in 2008, requires EU regions and Member States (MS) to build on 
their own strengths and to manage a priority-setting process in the context of national 
and regional research and innovation strategies. Research and innovation strategies for 
smart specialisation (RIS3) have been placed at the core of the new European cohesion 
policy as an important driver for the achievement of the Europe 2020 strategy objectives 
from a regional perspective. 
Smart specialisation, as a rationale for research and innovation policies, aims at 
promoting the collaboration between the regional and national authorities in charge of 
taking decisions on the design and implementation of the innovation policies and the 
relevant stakeholders involved in such a process (i.e., firms, entrepreneurs, universities, 
research centres, civil society). An assessment of existing national/regional assets 
implies looking 'inside' the country/region; however, this might be insufficient for a 
smart specialisation strategy. A major novelty of the S3 approach is that each 
country/region has to make its strategic decisions by taking into account their position 
relative to other regions of Europe. 
Smart specialisation requires EU MS and regions to focus their efforts and resources on a 
limited number of ambitious yet realistic priorities (niches or activities), where as a 
result, they would be able to develop excellence as well as compete in the global 
economy in a sustainable (financially, socially and environmentally) manner. When 
implemented, these strategies are expected to allow Member States and regions to 
strengthen their research and innovation systems, maximise knowledge flows, 
absorption and utilisation as well as spread the benefits of innovation throughout their 
economies.  
There has been a general recognition by policymakers that the S3 concept is an 
important step towards reaching the Europe 2020 goals. At the same time, the European 
Commission has formally introduced smart specialisation as a legal pre-condition or ex 
ante conditionality for using the European Regional Development Fund (ERDF) in the 
new funding period (2014–2020). As a result, as of 2014, national and regional 
authorities across the European Union are required to prepare their RIS3, so that the 
Structural Funds are used more efficiently with the aim of increasing synergies between 
different EU, national and regional policies, as well as public and private investments. 
Thus national and regional governments across the European Union have been 
developing RIS3 strategies based on the principle of smart specialisation.  
The RIS3 approach requires looking beyond the national/regional administrative 
boundaries. In other words, a country/region should be able to identify its competitive 
advantages through systematic comparisons with other countries/regions, mapping their 
national and the international context in search of examples to learn from, or to mark a 
difference with, and performing effective benchmarking. 
Moreover, each country/region should be able to identify relevant linkages and flows of 
goods, services and knowledge revealing possible patterns of integration with partner 
regions. This is important in the case of both developed and for less developed 
countries/ regions that would often require to source know-how and technology from 
elsewhere. In this context the significance and role of Global Value Chains (GVCs) merit 
consideration. The position of businesses within global value chains in this respect is a 
crucial element to be considered. This type of analysis is particularly important as the S3 
concept warns against 'blind' duplication of investments in other European regions. Any 
such blind duplication of efforts could lead to excessive fragmentation, loss of synergy 
potential, and ultimately could hamper the reach of the critical mass required for 
success. On the contrary, interregional collaboration should be pursued whenever 
similarities or complementarities with other regions are detected. 
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The above considerations led to a focus on the topic of GVCs in the context of S3 at the 
national peer review workshop that was held in Dublin on July 3-4, 2014 on the theme of 
‘Smart Specialisation: Moving Forward and Looking Outward’. The discussions and 
debates that took place at that event prompted the writing of this policy brief. The 
coverage of the policy brief extends to a methodological approach to analysing a 
country’s (region’s) position in GVCs in terms of activities, resources, assets and 
relationships.  
The brief contains an extensive and well-documented case study on how the 
methodology can be applied. The case study focuses on an industrial sector viz. the 
pharmaceutical industry. It does so in the context of Ireland analysing the industry from 
the GVC perspective and within the S3 context thus assessing Ireland’s current value 
proposition and pointing to where opportunities for further embedding of the industry in 
GVCs may exist. Accordingly, the paper represents the first attempt to understand S3 
from the perspective of GVCs. 
 
2. The Manufacturing Context 
 
‘The ideal strategy for a global company would be to put every 
factory it owned on a barge and float it around the world, taking 
advantage of short-term changes in economies and exchange rates’  
      Jack Welch, former CEO GE  
 
Recent decades have seen the global fragmentation of production1. Manufacturing has 
been transformed over recent decades with off-shoring including outsourcing 
contributing to significant changes in the Manufacturing landscape. Manufacturing has 
migrated to low cost economies while many established product firms in the developed 
economies have contracted out their manufacturing to specialist manufacturing firms.  
Today we have globalised manufacturing networks involving many source locations and 
actors so that the concept of ‘made in the world’ has entered the discourse. Thus instead 
of parts, components and sub-assemblies being locally procured, the import content of 
production has tended to increase in recent decades. Concurrent with the hollowing out 
of their manufacturing activities, product firms have sought to drive value creation by 
embracing new business models that incorporate elements of servitisation so that the 
provision of products is accompanied by the delivery of a service component. 
But there can be limits to the effective management of the complexity that large scale 
outsourcing entails especially when modularity involving design and manufacturing is 
low. And recently, there have been suggestions around the possibilities of a 
manufacturing renaissance in those economies which experienced a hollowing out of 
manufacturing over the past decades.  
Examples of near-shoring (the transfer of activity to a country near or adjacent to the 
home country) and re-shoring (the transfer of activity back to the home country) have 
recently been observed in the case of a number of firms. Apart from cost and nimbleness 
considerations, a number of other factors obtain. These include an increasing 
consciousness of the vulnerabilities of globally dispersed value chains, a recognition of 
                                           
1 Brennan, L., Ferdows, K., Godsell, J., Golini, R., Keegan, R., Kinkel, S., Srai, J.S. and 
M. Taylor (2015). Manufacturing in the World: Where Next? International Journal of 
Operations and Production Management Vol. 35, No. 9, pp. 1253-1274, 2015.  
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the benefits of co-location of design and manufacturing functions and an awareness of 
the limits to manufacturing fragmentation.  
This may suggest that we may perhaps be close to a tipping point in terms of the global 
dispersion of manufacturing activities. There are also suggestions that the drivers of 
manufacturing configuration are evolving so that proximity to demand and innovative 
supply ecosystems come to dominate manufacturing configuration strategy2. 
It is important to recognise that manufacturing is diverse and that fundamental 
differences exist between manufacturing industries 3 . Five broad groups (global 
innovation for local markets, regional processing, energy-/resource-intensive 
commodities, global technological innovators and labour-intensive tradables) that 
possess very different characteristics and requirements have been identified by the 
McKinsey Global Institute. These vary in their sources of competitive advantage and how 
different factors of production influence where firms locate factories, carry out R&D and 
go to market. As presented in Figure 1, these groups can be characterised in terms of 
their R&D intensity, labour intensity, capital intensity, energy intensity, trade intensity 
and value intensity. 
 
 
Figure 1: The Diversity of Manufacturing (Manyika, et al, 2012) 
 
They also vary in terms of the degree to which service type activities make up their 
employment (Figure 2). High performing manufacturers (i.e. those who consistently 
deliver exceptional performance) in the high tech sector have strong R&D capabilities 
                                           
2  George, K., Ramaswamy, S. and L. Rasey (2014). Next-shoring: A CEO’s guide. 
McKinsey Quarterly, January. 
3 Manyika, J., Sinclair, J., Dobbs, R., Stube, G., Rassey, L., Mischke, J., Remes, J., 
Roxburgh, C., George, K., O’Halloran, D. and S. Ramaswamy (2012). Manufacturing the 
future: The next era of global growth and innovation, McKinsey Global Institute, 
McKinsey and Company, November, pgs. 16. 
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and a highly skilled workforce, strong supplier networks and collaboration, with 
increasing leveraging of the innovation and talent of a strong supplier network especially 
for those firms for which rapid new product and service innovation is significant to their 
competitive strategy. Two key priorities that have been highlighted for both 
governments and businesses are education and the development of skills.  
In that regard, firms have to build their R&D capabilities, as well as expertise in data 
analytics and product design. Firms will need qualified, computer-savvy factory workers 
and agile managers for complex global supply chains. In addition to supporting on-going 
efforts to improve public education—particularly the teaching of math and analytical 
skills—policy makers must work with industry and educational institutions to ensure that 
skills learned in school fit the needs of employers.  
Managers will need to adapt to the demands of sophisticated equipment and systems, to 
more sophisticated and higher-value work requiring more skill and understanding and to 
harness the special capabilities of both automation and humans and ensuring that they 
collaborate effectively. Analysing occupations in terms of the tasks - routine and 
complex – that they involve, it is increasingly possible to programme and automate 
routine tasks, both manual and cognitive4. 
 
 
Figure 2: Service type activities in Manufacturing (Manyika, et al, 2012) 
 
3. The Value Chain and Global Value Chains 
The value chain describes the full range of activities that firms engage in to bring a 
product from its conception to its end use and beyond. This includes design, production, 
marketing, distribution and support to the final consumer (see Figure 3). The activities 
that comprise a value chain can be contained within a single firm or divided among 
different firms. Value chain activities can produce goods or services, and can be 
contained within a single geographical location or spread over wider areas. Global Value 
Chains are value chains that can be divided among multiple firms and dispersed across 
wide swaths of geographic space, hence the term ‘global value chain’5. 
                                           
4 Anon (2014). To those that have shall be given, Economist, October 04. 
5 www.globalvaluechains.org. Accessed on January 15, 2015.  
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Figure 3: The Value Chain 
Figure 4 provides an illustration of a global value chain based on Apple’s iPhone 4. In 
some instances, activities of the value chain may be embedded in established clusters 
that specialise in that particular activity. 
 
 
Source: adapted from OECD (2011) "Global Value Chains: Preliminary Evidence and Policy Issues", 
Organization for Economic Co-operation and Development, DSTI/IND(2011)3, Paris, 2011 
Figure 4: The Global Value Chain for Apple’s iPhone 4 
 
Hence cluster analysis that reveals the extent to which a cluster forms part of a global 
value chain or chains can provide important insights around GVC participation. Global 
Value Chains represent the enactment of globalisation which at its heart is about flows: 
flows of materials, goods, information, knowledge, finance and people. Global Value 
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Chains are the basis of such flows. The on-going construction, deconstruction and 
reconstruction of such chains provides the infrastructure through which globalisation is 
enabled. The design, configuration and coordination of such chains to achieve maximum 
business performance are central to the role of multinational enterprises (MNEs). 
Integrating emerging technologies into such chains to create symbiotic business systems 
that yield maximum performance is the key to competitive advantage in today’s 
globalised world. 
Global value chains make it possible to bring together all the raw materials & 
components that combine to make a product or service; to deliver it into use through 
distribution systems; to support users on a 24-hour basis; and to recover and integrate 
residue into a waste stream. These chains span the world, so that even mundane items 
now commonly involve the coordination of flows of goods, information, finance and 
people across several continents while navigating customs crossings, security screenings 
and identity verification. A global value chain may involve American designers, Indian 
software writers, Asian manufacturers and European system integrators and support 
provision. 
Global value chains (GVCs) are ‘organisational systems’ that operate across multiple 
nations, that are integrated, whose global integration is complex and whose technology 
base, or ‘engine’, is Information & Communication Technologies (ICT). Thus consistent 
with the role of ICT and related KETs as a means of upgrading activities in some sectors 
in countries/regions, they can also play an important role in GVC participation. GVCs 
drive firm-level competitive advantage through integrating global and local competitive 
and comparative advantages (firm specific & location specific advantages). 
They build & defend longer-term competitive advantage through complex and hard to 
imitate firm-level assets / capabilities. Global value chains evolve through stages of 
development, or may be ‘born global’. Thus for example, if we consider the value chain 
for the JCB 3CX backhoe loader it evolved from having virtually all of its inputs locally 
sourced in the 1970s to where about two thirds of its inputs were globally sourced by 
2010. By contrast, some firms such as some operating in the Internet space may 
operate within a value chain that is global from the 
birth of the firm. GVCs incorporate ‘traditional’ or 
‘conventional’ activities and functions but also involve 
‘whole system’ activities from sourcing to customer 
support and embody materials, information, financial 
and people flows and assets. 
Global Value Chains are complex. The complexity of 
these chains may be seen, for example, in the 
activities necessary to bring a new automobile to 
market. Flows of ore, steel, petrochemicals, 
performance plastics, glass, paint, rubber, mechanics, 
electrics, electronics, software, upholstery, to name 
just some elements, must be coordinated to take the 
form of automobile parts, components and sub-
systems. These inputs must all converge just-in-time 
in an assembly plant to be fashioned into an 
automobile. The output is then dispersed 
geographically again through distributors, dealerships 
and Internet vendors into final ownership and 
continuing service in the hands of individuals 
throughout the world. 
The value chain takes an ‘end-to-end’ perspective in terms of activities, resources, 
assets, capabilities, relationships and financial and operating data. This facilitates 
thinking holistically across the chain and identifying opportunities in terms of new ideas 
and innovations that could emerge from a questioning of what is, what is not and what 
Domestically produced 
value added of exports 
includes not only the direct 
value added created in the 
production of exported 
goods, but also the value 
added contained in its 
domestic inputs. 
Imported value added of 
exports is the value of the 
imported inputs used 
directly or indirectly to 
produce exports. 
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could be. As firms have sought to maximise returns, they have embraced various 
strategies directed towards value capture including slicing the value chain, outsourcing, 
off-shoring (either in-house or contracted out), repositioning on the chain and/or 
collaborating with other parties on the industry value chain. Thus firms determine value 
chain configurations, i.e. the way in which the activities of the value chain are spatially 
arranged within the constraints of product physical and knowledge characteristics. 
They take account of a multiplicity of factors that can include cost factors such as wage 
rates, productivity and inflation, the quality of business environments including the 
extent of political & economic risk, regulatory and tax considerations, technology, cluster 
effects involving related value creation activities, logistics considerations including value-
to-weight ratio and just-in-time practices, degree of digitisation, economies of scale and 
customer needs (that influence the requirement for, and location of buyer-related 
support activities)6. Other considerations that may obtain particularly in the case of high-
end manufacturing can include adequate infrastructure, talent availability, IP protection, 
energy costs and domestic supply networks.  
GVC analysis concentrates on how different tasks, activities and types of operations 
positioned in the value-chain are distributed across locations 7 . Higher volumes of 
intermediate products such as parts, components and intermediate services are being 
produced in stages or processes across different countries and then exported to other 
countries for further production. As highlighted by UNCTAD (2013)8, a country’s exports 
can be divided into domestically produced value added and imported (foreign) value 
added that is incorporated into exported goods and services. Furthermore, exports can 
either go to a foreign market for final consumption or as intermediate inputs to be 
exported again to third countries (or back to the original country). 
The analysis of GVCs takes into account both foreign value added in exports (the 
upstream perspective) and exported value added incorporated in third-country exports 
(the downstream perspective). Today, almost 60% of trade in goods is in intermediates 
and the average import content of exports is around 40% 9 . Given the increasing 
complexity and sophistication in GVCs, it has been difficult to identify who produces what 
kind of value for whom by what kind of activity in the chain10.  
Gaining insight into GVCs requires the following five steps of analysis as follows: 
i) Mapping as in plotting out their various stages across geographies and firms. 
ii) Digging into the each stage in terms of terms of activities, resources, assets, 
capabilities, relationships and financial and operating data. 
iii) Determining the chain orchestration in terms of actors, linkages and flows.  
iv) Decomposing the activities at each stage into occupations and associated 
tasks. 
v) Ascertaining the participation possibilities by considering not only the status 
quo from i) to iv) above, but by also anticipating likely future chain 
trajectories.  
 
 
                                           
6  Daniels, J.D., L. H. Radebaugh and D. P. Sullivan (2013). International Business: 
Environments and Operations, Pearson.  
7 Suder G., Liesch P.W., Inomata S., Mihailova I. and B. Meng (2014). The evolving 
geography of production hubs and regional value chains across East Asia: Trade in 
value-added, Journal of World Business. 
8 UNCTAD (2013). Global Value Chains and Development. Available at 
http://unctad.org/en/publicationslibrary/diae2013d1_en.pdf 
9 Lamy, P. (2013). "Emerging economies: ‘shapers and makers’ in changing landscape" 
– WTO News: Speech by DG Pascal Lamy at Bigli University, Istanbul. 
10 Suder et al. op. cit.  
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4. GVC Flows – Basic Concepts 
Three basic concepts of supply chain trade have been elaborated: ‘importing to produce’ 
(I2P), ‘importing to export’ (I2E) and ‘value added trade’ 11 . I2P encompasses all 
imported intermediate inputs including raw materials and services while I2E 
encompasses all foreign intermediates that are used to produce goods and services that 
are subsequently exported. Since I2E is a recursive concept, double counting is 
pervasive. Some 28% of the value of cross-border trade in goods and services is 
overstated as a result of double or multiple counting12.  
Growing global value chains means that a country's exports can increasingly rely on 
significant intermediate imports (i.e., value added by industries in upstream countries 
i.e. countries where value chain stages are based that preceded those of the country in 
question).  
A country's imported intermediates from another can contain intermediates from third 
countries and sometimes from the country itself. When these quantities are completely 
calculated – so that the origin of all primary factor inputs (the major primary factors are 
labour, capital, human capital (or skilled labour), land, and sometimes natural 
resources) in exports is identified – we have factor-content trade (the amounts of 
primary factors used in the production of a good or service that are traded), which is 
referred to as Value Added Trade.  
The OECD-WTO Trade in Value Added (TiVA) database13 is a resource that provides a 
number of useful measures on Global Value Chains and covers 95% of global GDP. These 
focus on the estimation of the source(s) of value (domestic vs. foreign and/or by country 
and industry) that is added in producing goods and services for export14.  
However, the broad sectoral classification for which these are presented hides important 
supply-chain specialisation occurring within sectors. It can also make sectoral 
comparisons between countries somewhat problematic. For example, the chemical sector 
in the TiVA tables can combine both base chemicals and pharmaceutical products. These 
subsectors differ in their use of intermediate products as well as their skill intensity and 
the TiVA outputs do not allow us to distinguish between which is being produced. 
The database is organised by 58 countries incorporating all OECD countries and the 
major emerging economies and including EU27 countries. An industry classification 
based on ISIC Rev.3 provides a range of outputs for 1990, 1995, 2000, 2005, 2008 and 
2009. These outputs incorporate gross trade indicators, value added embedded in gross 
trade flows, intermediate imports, value added embedded in final domestic demand and 
foreign final demand and revealed comparative advantage.  
In addition, country and industry indicators that measure the importance of GVCs can be 
obtained from the data base. These measures are the following: the GVC participation 
index, the GVC length and the index of distance15 to final demand (see Box 1). 
Data on value added trade by industry can provide useful indications on comparative 
advantages and competitiveness of countries, and hence form a basis for development 
strategies and policies16. 
                                           
11 Baldwin R. and J. Lopez-Gonzalez (2014). Supply-Chain Trade: A Portrait of Global 
Patterns and Several Testable Hypotheses. The World Economy.  
12 Backer, K. D. and S. Miroudot (2013). Mapping Global Value Chains, OECD Trade 
Policy Papers, No. 159, OECD 
13 http://www.oecd.org/industry/ind/measuringtradeinvalue-addedanoecd-
wtojointinitiative.htm  
14 OECD (2013). Interconnected Economies: Benefiting from Global Value Chains. 
15 UNCTAD (2013). op. cit.  
16 UNCTAD (2013). op. cit. 
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5. Value-chain trade flows 
The big value-chain trade flows have been demonstrated to be in sectors such as 
transport equipment, electrical and optical equipment and chemicals17. Final-good shares 
of production have reduced in all sectors from 1995 to 2009 which is evidence that value 
chains have fragmented and that about half of the world's output of goods and services 
are sold as intermediate inputs.  
The world is still more globalised for final goods than it is for intermediates; the 
domestic-sales-to-export split is about 60–40 for final manufactures while it is about 70–
30 for intermediates. Overall, world production is not yet very internationalised with the 
imported intermediates share of total world manufacturing at only 16 per cent and 8 per 
cent for the production of all goods and services18. 
At the level of aggregation available today, most nations are largely self-sufficient in 
terms of intermediate inputs. However, smaller economies (e.g. Hungary) and certain 
sectors (e.g. electronic goods exports) have typically higher ratios of imported 
intermediate goods destined for the export market. At the same time, 80% of global 
trade is accounted for by value chains administered by MNEs such that global investment 
and trade ‘are thoroughly entwined international production networks’19. The emergence 
                                           
17 Baldwin R. and J. Lopez-Gonzalez  op. cit. 
18 Baldwin R. and J. Lopez-Gonzalez  op. cit. 
19 UNCTAD (2013). op. cit. 
 
Box 1: Three measures of the importance of GVCs 
The GVC participation index indicates the extent to which a country is involved as 
part of a multi-stage trade process involving a vertically fragmented production 
process both as a user of foreign inputs for its own exports (measured as the value of 
imported inputs in the overall exports of a country, backward participation) and as a 
supplier of intermediate goods or services used in other countries’ exports (measured 
as the percentage of exported goods and services used as inputs to produce other 
countries’ exports, forward participation).  
The higher the foreign value-added embodied in gross exports and the higher the 
value of inputs exported to third countries and used in their exports, the higher the 
participation of a given country in the value chain. 
The index of distance to final demand addresses the question of where countries are 
located in the value chain. It measures how many stages of production are left before 
the goods or services produced by an industry in a given country reach final 
consumers. 
The GVC length: The participation index does not provide information about the 
length of the value chain, i.e., the number of stages of production involved. The 
index of the number of production stages indicates how long the global value chains 
are and also highlights the domestic and international part of the value. This 
dimension may also be useful in terms of providing an indication of the scope for 
countries upgrading within GVCs, assuming that one can argue that longer (more 
fragmented) value chains provide more opportunities since they offer a greater 
number of participation possibilities. 
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of GVCs suggests major paradigm changes 20 . These include a change of relevant 
strategic framework, from countries to firms and GVCs. Since a country cannot develop a 
competitive offer of goods or services in isolation, imports are a means for firms to 
access the most efficient inputs and free resources to focus on core competences. In 
addition, trade and FDI, both inward and outward, should be treated in an integrated 
framework. 
A second paradigm change that has been highlighted21 relates to a change of relevant 
economic framework, from industries to tasks and business functions. In this regard, the 
objective is not to develop domestic industries that would capture all the segments of 
production or the whole value chain. Rather it is to identify the country’s best position in 
the GVC and the most competitive supply of tasks or business functions and 
acknowledging that an efficient manufacturing sector requires efficient and competitive 
services (e.g. financial intermediation, R&D, logistics, and marketing) as well as a skilled 
workforce and continuous innovation in products, processes and business models.  
Thus it has been concluded that countries do not need to develop vertically integrated 
industries to participate in global trade but rather to develop capacities in specific 
segments (stages of production, tasks or business functions) of the value chain.  
In this respect, Baldwin’s TOSP (Tasks, Occupations, Stages and Product) framework22 
provides a useful means of identifying the possibilities for global value chain positioning 
(see Figure 5). A further paradigm change relates to a change in the relevant economic 
assets from endowments and stocks to flows23. GVCs have become the main channel of 
transfers such as capital, knowledge, technology standards and value-added services. 
 
 
Figure 5: Tasks, occupations, stages and product – the TOSP framework  
(Baldwin, R. (2012) Global Supply Chains: Why They Emerged, Why They Matter, and  
Where They Are Going, Working paper FGI-2012-1, Fung Global Institute, July). 
 
  
                                           
20 Cattaneo, O., Gereffi, G., Miroudot, S. and D. Taglioni (2013). Joining, upgrading and 
being competitive in global value chains: a strategic framework, Policy Research 
working paper; no. WPS 6406. The World Bank. 
21 Cattaneo et al (2013). op. cit. 
22 Baldwin, R. (2012). Global Supply Chains: Why They Emerged, Why They Matter, and 
Where They Are Going, Working paper FGI-2012-1, Fung Global Institute, July. 
23 Cattaneo et al (2013). op. cit. 
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6. GVCs and Smart Specialisation 
Trade and participation in GVCs are just intermediary objectives 24 . Instead the key 
consideration is how much value is captured by the country in terms of jobs, income, 
technology diffusion, sustainable development, etc. The ability of a country to participate 
in global trade and benefit from the transfers that will generate growth and development 
is now partially linked to its ability to join GVCs. Thus competitiveness is not measured 
in terms of a country’s capacity to develop an integrated industry, but its capacity to 
identify its best position in GVCs. A country’s competitiveness can be assessed at three 
levels relating to its capacity to join GVCs, remain part of GVCs and move up the value 
chain within GVCs. A further issue is a country’s capacity to disrupt GVCs which requires 
a somewhat different set of considerations. 
Finally, in considering the potential to benefit from participation in GVCs, trade in 
integrated regions such as the European Union are more attractive to GVC lead firms for 
a number of practical reasons due to greater ease and lower costs of flows. Lead firms in 
GVCs carry brands and sell branded products and systems in final markets to individual 
consumers, other businesses, or government agencies.  
These firms initiate, or ‘lead’, the GVC’s activities by placing orders with suppliers, giving 
them market power over suppliers25. In this respect, the European Union could develop a 
number of competitive industries through the constitution of regional value chains as 
already demonstrated in the case of Airbus in aeronautics (see Figure 6). 
 
 
Figure 6: Assembly of an Airbus A350 Wing (www.flightglobal.com) 
                                           
24 Cattaneo et al (2013). op. cit. 
25  Sturgeon, T. and M. Kawakami (2010). Global Value Chains in the Electronics 
Industry: Was the Crisis a Window of Opportunity for Developing Countries?  Policy 
Research Working Paper 5417. The World Bank. September.  
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In addition, it has been observed that a number of value chains tend to be regional, such 
as the bulk of the automotive industry26. However, it has argued that the objective is not 
necessarily to develop an integrated industry, but to capture an important part of the 
chain’s value-added by providing a regional bundle of tasks or services at pinch points of 
the GVC where opportunities can arise27. 
 
7. Manufacturing in Ireland  
Given that this brief focuses on one element of Ireland’s manufacturing sector, it is 
important to offer some perspective on that sector. Manufacturing plays a critical role in 
the Irish economy – as a driver of exports, as an employer, as a source of revenue and 
as a key driver of growth. In total, there are 12,790 manufacturing enterprises in 
Ireland. Most of these are small in scale, with 83 per cent employing less than 10 people 
(micro firms) and 95 per cent employing less than 50 people. In general, the larger firms 
are foreign owned, with the exception of a small number of firms involved in the food 
and engineering sectors. Overall, firms assisted by the two state agencies (the Industrial 
Development Agency (IDA) with responsibility for foreign enterprises and Enterprise 
Ireland (EI) with responsibility for indigenous owned enterprises) represent 
approximately 92 per cent of total manufacturing employment. Historically employment 
in manufacturing firms by ownership has been split almost evenly between Irish-owned 
and Foreign-owned firms. 
In its report ‘Future Skills Requirements of the Manufacturing Sector to 2020’28, the 
Expert Group on Future Skills Needs predict, under the Competitive Manufacturing 
Scenario, employment to rise by 22,000 to 2016 and continue incrementally to increase 
by 43,000 by 2020. The report identified the skills needs for manufacturing generally 
and some specific needs for a number of manufacturing subsectors, namely; 
Engineering, Biopharma-Pharmachem, Medical Devices, Food & Beverages Consumer 
Products and ICT Hardware. Manufacturing firms across all sub-sectors reported that 
professional engineering and science occupations for those requiring experience, were 
the most frequently mentioned as being difficult to fill. Ireland has a developed National 
Innovation System that is currently based around a set of priority areas for publicly 
funded research. Several of these priority areas relate to Manufacturing. This is 
consistent with the EU’s positioning of Advanced Manufacturing as a KET. Ireland has 
made a significant investment in this KET in the last decade and is currently funding a 
number of Research and Technology centres which focus on Advanced Manufacturing, 
including a Materials & Surface Science Institute (MSSI), Tyndall National Institute, Irish 
Centre for Manufacturing Research (ICMR), and the I2E2 energy efficiency research 
centre. 
Since the 1990s Ireland has invested in its research infrastructure through the direct 
funding of third level education institutions via a number of programmes for research – 
Programme for Research in Third Level Institutions (PRTLI) and through Science 
Foundation Ireland (SFI). In the case of SFI, it has funded the establishment of 
specialised research centres in a number of priority areas predominately in the 
Biotechnology and ICT fields since it was founded in the 1990s. These initiatives have 
                                           
26 Sturgeon, T. ,  Memedovic J. Van Biesebroek and G. Gereffi (2009). Globalization of 
the Automotive Industry: Main Features and Trends, International Journal of 
Technological Learning, Innovation and Development, 2(1-2), pp. 7-24.  
27 Cattaneo et al (2013). op. cit. 
28 Forfas (2013). Future Skills Requirements of the Manufacturing Sector to 2020 Expert 
Group on Future Skills Needs, February. 
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both expanded and upgraded the pool of human capital in Ireland. They have been 
driven by the objectives of developing world-class research capabilities in strategic 
technologies to underpin the future development and competitiveness of Irish owned 
industry, facilitating the undertaking of R&D in Ireland by multinational companies in 
order to support the further development of that sector in Ireland, attracting more high 
technology companies to Ireland in the future, and enhancing the environment for the 
creation of new technology-based firms 29 . Ireland’s enterprise policy is focusing on 
realising the economic benefits of its investments to date in R&D infrastructures, by 
strengthening its IP framework, by brokering partnerships between firms and research 
institutes, and by reducing barriers for SMEs to engage in RD&I30. 
 
8. The Pharmaceutical Industry 
Since the Pharmaceutical sector is a highly globalised, innovation-driven industry with 
extensive co-operation and competition between large and small companies (OECD, 
2013), it represents an appropriate sector to focus on in the context of GVCs and S3. 
The industry can be categorised into three groups: i) Biotechnology firms, ii) Traditional 
pharmaceutical companies – or more commonly known as ‘Big Pharma’ and. Iii) Generic 
drug companies. These three groups have tended to possess distinct capabilities and 
specialisation. Whereas Big Pharma dominated the industry for decades, the emergence 
of biotechnology firms and generic drug companies have undermined that dominance 
and threatened its traditional business.  
The kinds of knowledge-based capital that support the competitive advantage of these 
three players in the pharmaceutical value chain have been considered31. The competitive 
advantage of biotechnology firms depends on advanced technological knowledge. This 
knowledge is built up not only through basic research but also through formal and 
informal collaboration on R&D with universities, other biotechnology firms and other 
actors with relevant technological competencies. A rich research network is thus a crucial 
asset of successful biotechnology firms.  
Big Pharma’s capabilities for identifying commercially promising breakthroughs stem 
from knowledge of the latest technologies and market environments and of networks of 
biotechnology firms and other actors able to produce novel solutions, as well as a 
reputation as a reliable collaborator. Big Pharma companies’ ability to commercialise 
breakthroughs swiftly is supported by its experience in laboratory testing and regulatory 
approval procedures. Finally, large networks of customers and recognised brand names 
are important for marketing their drugs globally. Generic drug companies that thrive on 
the basis of cost competitiveness rely on efficient procurement networks to reduce 
material costs and a wide network of customers.  
Developments in Biotechnology have spurred the growth of biotechnology firms and 
have steadily increased the significance of the biopharmaceutical (‘biopharma’) segment 
of the industry particularly in recent years with its rapid advance. While the biopharma 
sector is a relatively new area of the pharmaceutical industry, with the first 
biopharmaceutical drugs being approved in the 1980’s and 1990’s, forecasts predict that 
by 2016, seven of the top 10 blockbuster drugs will be biopharmaceuticals.  
                                           
29 Ireland’s Smart Specialisation Strategy for Research and Innovation Background 
Paper  S3 Platform Peer Review Workshop  Dublin, 3-4 July 2014. 
30 Ireland’s Smart Specialisation Strategy for Research and Innovation Background 
Paper op. cit. 
31  Haanes, Knut and Fjeldstad, Øystein (2000.) Linking Intangible Resources and 
Competition, European Management Journal. Vol. 18, Nº1, pp.52-62. 
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Biopharma manufacturing is complex and challenging due to the extreme complexity and 
variability of the process and the product and the highly regulated nature of the 
industry. Bioprocessing is regarded by the EU as a Key Enabling Technology (KET) with 
applications in multiple fields of manufacturing including medicine production and 
industrial processes and having a high potential for economic impact albeit involving a 
high level of Capital Expenditure and risk.  
From a GVC perspective, the Pharmaceuticals industry is an example of where producer-
driven, as opposed to buyer-driven GVCs, obtain. Producer-driven GVCs tend to be found 
in high-tech sectors that rely on technology and R&D. In such chains, lead firms are 
found upstream and control the design of products as well as most of the assembly 
which is fragmented in different countries32. 
 
9. The Pharmaceutical Industry in Ireland 
The Pharmaceutical industry forms an important part of the manufacturing sector in the 
Irish economy. Initial investments in the sector were primarily in bulk pharmaceuticals, 
now known as active pharmaceutical ingredients (APIs). Over the course of the 1970s, 
investment began to gravitate towards drug product manufacture. The 1990s saw this 
trend continue, with many established sites reinvesting significantly and expanding into 
shared service activities. The advent of the human genome project saw many Irish-
based companies invest in biotech or biopharmaceutical operations. Currently, many 
players are investing in product and process development, thereby adopting the 
Development & Manufacturing model. In addition, a number of indigenous specialist 
pharmaceutical and chemical companies have been established, adding to the overall 
diversity of the sector33. 
The majority of Irish sites have undergone significant transformation since they first 
established. This has helped Ireland to move away from its traditional status as a 
sourcing location, primarily for APIs. Many sites are now engaging in fully-integrated 
operations, offering a range of activities beyond pure manufacturing, including process 
and product development, manufacture for clinical trials, shared services, etc.  
9 out of the top 10 world’s pharmaceutical companies have substantial operations in 
Ireland. There are over 30 FDA approved pharma/bio plants located in Ireland. There is 
a strong and transparent regulatory framework in force provided by IMB, FDA and EMA 
with an extraordinary compliance and regulatory track record. There are approximately 
25,000 people directly employed in the industry with an almost similar number indirectly 
employed providing support services. In 2012, exports of 55 billion euro were reported. 
In that year Ireland was the 8th largest producer of pharmaceuticals in the world and 
accounted for almost 4% of global Pharma-chem exports. Pharma-chem accounted for 
circa 45% of Ireland’s merchandise exports in 2012.  
The Pharmaceutical sector in Ireland can be grouped into four main sub-groups: Primary 
Pharmaceuticals, Secondary Pharmaceuticals, Diagnostics and Biopharmaceuticals34. 
The industry in Ireland has been responding to the global trends in the industry with 
value chain upgrading and an increasing concentration on bio-pharma. Irish subsidiaries 
are repositioning themselves in the global value chain as ‘strategic launch plants and 
                                           
32 Backer, K. D. and S. Miroudot (2013). op. cit. 
33 This paragraph and the next paragraph drawn from IBEC’s Ireland Strategy in Action 
available at http://www.pharmachemicalireland.ie/Sectors/PCI/PCI.nsf/vPages/PCI_ 
policy~Publications_and_Resources~strategy-in-action/$file/Strategy in Action.pdf 
34 Sourced from Enterprise Europe Network (2010). Pharmaceuticals in Ireland. 
Available at http://www.een-ireland.ie/eei/assets/documents/uploaded/general/ 
Pharmaceuticals Fact sheet.pdf  
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flexible multi-product plants’ that can produce the high-value stages of the chemical 
pharmaceutical process as well as small volume, high value niche products 35 . The 
improvement in Ireland’s R&D offering through the introduction and subsequent 
enhancement of the R&D tax credit coupled with the steps taken to develop the national 
science and technology infrastructure and upgrade the pool of human capital has led to 
greater R&D activity. This has been particularly pronounced in the area of process R&D 
with the co-locating of process R&D activity with existing manufacturing operations. With 
the growth of activity in the bio-pharma segment of the industry, Ireland has seen the 
development of a cluster in the area with over ten large-scale biopharmaceutical 
facilities. In all the total up and running or in planning by late 2014 was nineteen as 
compared to ten years earlier when there was only one facility36. More than 5,000 people 
were employed in Biotech development and manufacturing in 2014 with a 7% 
employment growth per annum since 2009. Ireland’s track record in the industry, its 
talent pool, tax advantages, regulatory stability and a national innovation system that 
encompasses extensive collaborations with the education sector have been important 
factors in the embedding of the pharmaceutical industry in Ireland via value chain 
upgrading and positioning in the fast-growing bio-pharma segment. 
Ireland’s ambition is to be the hub of excellence in development and manufacturing for 
pharma-chem/biopharma with Ireland as the location of choice and with strategically 
relevant activities at the centre of the global supply chain. The movement towards the 
production of biopharmaceuticals on the part of existing companies coupled with the 
entry of new companies in the segment involves an upskilling for the industry. Globally 
the challenge of securing suitably skilled and experienced labour at all levels is 
considered to be the greatest constraint facing the fast growing biopharma segment. 
Ireland has responded to this challenge with the establishment in 2011 of the National 
Institute for Bioprocessing Research and Training (NIBRT) Centre involving a partnership 
with industry and four leading academic institutions. In addition to the establishment of 
the NIBRT centre, Ireland has also invested in the establishment of the SSPC (Synthesis 
and Solid State Pharmaceutical Centre) and the PMTC (Pharmaceutical Manufacturing 
Technology Centre).  
The strategic development of the Pharmaceuticals industry and of the biopharma 
segment of the industry in particular represents an instructive demonstration of smart 
specialisation in Action via GVC specialisation and the embrace of a holistic approach to 
development.  
                                           
35 Enright, Shane and Dalton, Mary. The Impact of the Patent Cliff on Pharma-Chem 
Output in Ireland, SSISI paper, March 2014. 
36 Cantillon, 2014. Biotech throws Ireland a valuable lifeline, Irish Times November 15, 
2014, pg. 20. 
Box 2: National Institute for Bioprocessing Research and Training (NIBRT) 
Centre 
The state-of-the-art facility was funded by the Irish Government (IDA Ireland) and 
counts among its clients many of the leading companies in the industry. Its mission is 
to conduct world-class research in key industrial areas of bioprocessing, to train highly 
skilled personnel for the bioprocessing industry and to provide flexible, multipurpose 
bioprocessing research and training facilities. 
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The strategy is closely aligned with Europe’s KETs and Ireland’s own Research 
Prioritisation. Ireland’s Smart Specialisation in Biopharma is aligned very closely with the 
four Cs of Competitive Advantage based on the matching of R & I with business and 
the development of links, the adoption of technologies for diversification/modernisation 
of sectors and the exploration of emerging areas, policy Choices involving the selection 
of a limited number of priorities based on specialisation & integration in international 
value chains, Critical Mass of resources & talent and Collaborative Leadership 
involving stakeholders from academia, businesses, public administrations and civil 
society (i.e. quadruple helix) & synergies between funding instruments (EU, national, 
regional). 
 
10. Ireland’s Pharmaceutical Industry in a GVC context  
In section 3, the steps involved in gaining insight into GVCs were detailed as Mapping, 
Digging, Determining, Decomposing and Ascertaining (or M3DA for short). The analysis 
presented below of Ireland’s Pharmaceutical Industry in a GVC context focuses on the 
first step around mapping. To this end, use is made of the TiVA database.  
In relation to this sector, the TiVA database contains data on Chemicals and non-metallic 
mineral products (ISIC Rev.3 codes 23-26). Although not an exact representation of the 
Pharmaceutical Industry, it does represent in the case of Ireland a close approximation 
of the Irish industry given the dominance of Pharmaceuticals in that grouping. 
Accordingly, we draw conclusions on the industry using the data for that grouping in the 
TiVA database. 
a) Comparative positioning: We first examine the Irish industry’s comparative 
positioning by considering both the revealed comparative advantage based on 
gross exports and based on domestic value added embodied in gross exports 
from 1995 to 2009 (see Figures 7 and 8). We find that in the case of both 
measures, Ireland’s Pharmaceuticals Industry revealed comparative advantage 
has more than doubled in that time frame. 
 
 
Figure 7: Revealed Comparative Advantage Based on Gross Exports 
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Figure 8: Revealed Comparative Advantage Based on  
Domestic Value Added Embodied in Gross Exports 
 
 
b) Focusing on gross trade indicators and value added embodied in gross 
trade, we find that the industry exports globally with its largest exports going to 
Europe and in particular Belgium, France, Germany, Switzerland the UK, and to 
the USA (see Figure 9).  
 
 
Figure 9: Gross Exports of the Irish Pharmaceutical Industry 
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Likewise its largest imports come from Europe and in particular France, Germany, 
the Netherlands and the UK, and from the USA (see Figure 10). Ireland’s gross 
trade surplus has increased from under $4 billion in 1995 to over $38 billion in 
2009 or as a percentage of GDP from 5.29% to over 17%. 
 
 
Figure 10: Gross Imports of the Irish Pharmaceutical Industry 
 
Looking at value added embodied in gross exports (Figure 11), we find that the 
proportion of domestic value added content of exports increased from about two-
fifths in 2000 to almost two-thirds in 2009.  
 
 
Figure 11: Total Domestic Value-added Content of Exports 
 
When we consider the direct contributions made by the industry (see Figure 12) 
and the indirect contributions of domestic supplier industries made through 
domestic (upstream) transactions (Figure 13), we note that the contribution 
made by domestic supplier industries increased greatly from 2005 to 2009. The 
re-imported domestic value added is low attaining some $80 million in 2009. 
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Figure 12: Direct Domestic Industry Value Added Content of Gross Exports 
Figure 13: Indirect Domestic Content of Gross Exports 
(Originating from Domestic Intermediates) 
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The foreign value added content of gross exports has fluctuated over the period 
1995 to 2009 with the latest figure for 2009 at about one third. The breakdown 
by country of origin is presented in Figure 14 with European countries and the 
USA representing the greatest sources with India also featuring. 
 
 
Figure 14: Foreign Value Added Content of Gross Exports by country of origin 
 
Exports of value added as represented by domestic value added embodied in 
foreign demand by importing country are represented in Figure 15. European 
economies along with the USA and to a smaller extent Japan are the major 
importing countries. 
 
Figure 15: Domestic Value Added Embodied  
in Foreign Final Demand by importing country 
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The Services added value embodied in gross exports for the industry was about 
one third in 2009. This includes payments for intellectual property. The major 
source countries are shown in Figure 16 and the trend in the amount of foreign 
services value added in gross exports is given in Figure 17.  
Figure 16: Services Value Added  
Embodied in Gross Exports by Source Country 
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4% 
37% 
9% 
22% 
28% 
Services Value Added Embodied in Gross Exports by 
Source Country for the Irish Pharmaceutical Industry 
Germany
Ireland
United Kingdom
United States
Rest of the World
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
1995 2000 2005 2009
U
SD
 m
ill
io
n
 
Foreign Services Value Added Content of Gross 
Exports for the Irish Pharmaceutical Industry 
  
 
25 
A notable feature is the rapid growth recorded in Indirect Domestic Services 
Value Added Content of Gross Exports in 2009 compared to earlier periods (see 
Figure 18). 
 
 
Figure 18: Indirect Domestic Services Added Value Content of Gross Exports  
(Originating from Domestic Intermediates) 
 
 
c) Focusing on intermediate imports, we first consider the share of intermediate 
imports used in producing exports, as a percentage of total intermediate exports. 
This provides a measure of the importance of intermediate imports to produce 
exports and their role as a source of international competitiveness. As presented 
in Figure 19, over half of intermediate imports are used in producing exports and 
there is limited variation evident in this proportion in the time frame considered. 
 
 
Figure 19: Re-exported Intermediates 
 as a % of Total Intermediate Imports 
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d) We next consider the GVC participation indices (Figures 20-22).  
 
 
Figure 20: Participation Index 
 
 
 
Figure 21: Participation Index (backward) 
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Figure 22: Participation index (forward) 
 
The overall index recorded for 2009 was ranked in the top five (Figure 23) 
indicating that Ireland’s industry is relatively highly involved as part of a multi-
stage trade process and that it is a relatively high participant in the industry 
global value chain. Significantly the nature of that involvement has changed over 
the time with the industry becoming less dependent on foreign inputs (Figure 21) 
and contributing more inputs to other countries’ exports (Figure 22). Thus the 
industry has become less reliant on inputs from outside Ireland and at the same 
time has embedded itself more significantly into the global value chain as it has 
increased its inputs into other countries’ exports. 
 
 
 
Figure 23: Top 20 Countries’ Participation Index for the Chemicals Industry  
(recall this is a close approximation for Ireland’s Pharmaceutical Industry) 
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e) Ireland’s index of distance to final demand (Figure 24) positions Ireland in the 
top 20 per cent of countries in terms of the ‘upstreamness’ of its industry. Thus it 
is relatively more specialised in the production of inputs at the beginning/early 
stages of the global value chain. This is significant since the industry value chain 
is producer driven and hence the desirability of being positioned upstream.  
 
 
 
Figure 24: Index of Distance to Final Demand 
 
f) The index of the number of production stages data (Figures 25, 26 and 27) 
reveal that Ireland has positioned itself in a greater number of stages of the 
global value chain over time. 
 
 
 
Figure 25: Index of the Number of Production Stages 
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Figure 26: Index of the Number of Domestic Production Stages 
Figure 27: Index of the Number of International Production Stages 
Thus from the perspective of our GVC analysis, it is evident that the Irish 
Pharmaceuticals industry is well established and that its trajectory over the time period 
1995 to 2009 has seen the industry position itself more effectively within a GVC context.  
A recent study has positioned Ireland in ninth position in terms of its centrality in the 
global pharmaceuticals industry37. Ireland’s high participation indices in Pharmaceuticals 
can be related to investments of large pharmaceutical companies, especially from the 
USA38. Furthermore in a ranking39 of top European biopharma clusters based on inter ala 
37 Hu, Y., Scherngell, T., Qiu, L.  and Y. Wang (2015). R&D internationalisation patterns 
in the global pharmaceutical industry: evidence from a network analytic perspective, 
Technology Analysis & Strategic Management.   
38 Backer, K. D. and S. Miroudot (2013). op. cit. 
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public research funding, venture capital (VC) funding, patents and number of companies, 
Ireland was ranked 10th. This high ranking was driven by the relatively high number of 
companies and the size of VC funding and less so by the level of public research funding 
and number of patents.  
By applying the above analysis, we can derive a number of important insights into the 
industry and its positioning within a GVC context. For example, we can see where the 
value added associated with the industry is produced, whether domestically or imported, 
and if the latter what are the most significant source countries. Likewise, in terms of 
domestically produced value added, we can see what its most significant destination 
countries are. Thus we are able to map the extent and magnitude of the industry’s 
linkages with other locations of the GVC.  
At the same time, as we have seen we can compare the industry to those in other 
countries in terms of participation within a GVC context, the number of stages of the 
value chain captured by Ireland relative to overall length of the value chain and that of 
other countries and where along the value chain, Ireland’s industry tends to be more 
concentrated. Importantly we can see how the industry has evolved over the time frame 
from 1995 to 2009 in terms of its activities, relationships and flows. Finally, the insights 
derived from the analysis enable a benchmarking of the industry to be obtained within a 
GVC context over time. All of the above insights are essential input into the development 
of any RIS3 strategies related to the industry.  
Our GVC mapping of the pharmaceutical industry in Ireland has revealed that it has 
progressively evolved over time. Ireland’s comparative advantage has improved over the 
time period considered. Its participation in the industry GVC is high and as noted earlier 
the nature of that participation has changed over time so that it is contributing more 
inputs into the exports of other countries while relying less on the inputs of other 
countries for its exports. Furthermore, it has moved up the value chain by positioning 
itself more upstream in the value chain and along a greater part of the value chain. All of 
the above suggests a deepening embedding in the industry GVC. From the viewpoint of 
other countries and regions seeking to integrate industries into GVCs, the learning from 
the experience of the Irish Pharmaceutical industry includes the importance of 
embracing a holistic approach to development and aligning its S3 closely with the four Cs 
of Competitive Advantage, Choices, Critical Mass and Collaborative Leadership.  
For Ireland itself, this mapping suggests that it needs to intensify its current approach. 
Simply maintaining its current approach is unlikely to suffice in terms of maintaining its 
GVC positioning and almost certainly not in terms of further moving up the value chain. 
As highlighted earlier, Ireland’s pharmaceutical industry falls short when ranked on the 
basis of public research funding and number of patents. Arguably, the paucity of patents 
relative to other locations can be attributed, at least in part, to its lower level of public 
research funding. Thus further investment in the development of advanced scientific 
human capital appears necessary as does the promotion and facilitation of greater 
collaborations on the part of the established research entities in Ireland with the leading 
established research entities in other countries and regions.  
Accordingly, the development and upgrading of scientific human capital and the forging 
of collaborations with leading research entities elsewhere need to be pursued as a 
priority. These steps should result in greater success for Ireland in gaining European 
research funding leading in time to an increase in the number of patents and hence to 
new commercial possibilities within the industry GVC.  
 
  
                                                                                                                                   
39 Top ten European Biopharma Clusters. Available at http://www.genengnews.com/ 
insight-and-intelligenceand153/top-10-european-biopharma-clusters/77900407/ 
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11. Conclusions 
 
This brief has considered GVCs within the context of smart specialisation. A 
methodological approach has been described that analyses a country’s (region’s) 
position in GVCs. This approach has been applied to the case of the pharmaceutical 
industry in Ireland. A similar approach can be applied to other locations pertaining to 
that industry or other industries. By doing so, the comparative advantage of the industry 
can be assessed and its degree of participation in the industry GVC can be assessed 
including establishing those locations that serve as its main sources of inputs and 
destinations of its outputs. Thus the linkages of the industry and their extent can be 
established.  
At the same time, the analysis can reveal where along the value chain the industry is 
positioned and the extent of that positioning. Thus the analysis points to opportunities 
for maintaining/extending/deepening the country’s positioning on the GVC. Furthermore, 
by applying a similar analysis to other locations, a location can ascertain who else 
occupies significant parts of the industry value chain, and how strong their positions are 
and whether those clusters of GVC activities in these other competing regions/countries 
are similar/complementary to their own activities. Taking account of the previously 
identified linkages, this can indicate whether there might be opportunities to capitalise 
on complementarities in other locations and the development of inter-regional/trans-
European linkages. To explore such opportunities requires engaging in the digging (D) 
stage of our MD3A process described in the brief. This implies a focus on the extant 
clusters of the industry GVC. 
Since the data required at the digging stage may be unavailable or indeed difficult to 
access, there is a need to identify conduits/boundary spanners who are connected to the 
industry and have a deep knowledge of the industry cluster and its characteristics. These 
conduits/boundary spanners are likely to be found within national and regional 
development agencies and/or enterprise development agencies. For each location, one 
such individual might be assigned an S3 responsibility within the context of the industry 
GVC. Platforms – real and virtual - would need to be developed to facilitate engagement 
among such conduits/boundary spanners so that opportunities for intra-regional industry 
GVC linkages can be precisely identified and pursued and that match-making takes 
place.  
This paper has highlighted a number of important matters in relation to GVCs and S3. 
These are now considered from the specific context of the case of the Irish 
pharmaceutical industry and more generally from a methodological perspective. From 
the Irish case we can suggest some general principles that can be followed. These entail 
the following: 
I. Engaging with the Industry and its stakeholders on a continuous basis, 
II. Anticipating the likely evolution of the Industry globally, 
III. Assessing the challenges and opportunities that are likely to ensue from 
future industry trajectories, and 
IV. Responding to those challenges and opportunities in a proactive manner.  
 
This process of Engaging, Anticipating, Assessing and Responding (EAAR) is required to 
be followed on an on-going basis and must involve the active participation of all 
stakeholders. The on-going success of Ireland in the changing Pharmaceutical Industry is 
an instructive example of RIS3 in action from which specific lessons can also be 
observed: 
I. The provision of a compatible and supportive environment via a relevant 
infrastructure that encompasses a robust regulatory framework, research and 
technology and education. 
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II. The upgrading and sustaining of a national innovation system. 
III. The development of the requisite human capital pool.  
IV. The supporting and nurturing of collaboration among all stakeholders. 
V. The engagement in upgrading of existing activities in the industry and 
VI. The anticipating and targeting of areas of growth within the industry. 
Finally in relation to some methodological perspectives, we have already observed that 
the macro analysis followed in the preceding section and applied to the Irish 
pharmaceutical industry offers very useful insights into the industry within a GVC 
context. However, this represents one stage of the M3DA process outlined in Section 3 
viz. the mapping (M) stage. The subsequent stages of digging, determining, 
decomposing (3D) and ascertaining (A) call for micro level analyses. These are 
particularly important if regional authorities are to play a role in co-creating and 
developing European industrial value chains based on smart specialisation priorities. 
This calls for the interregional knowledge building, mapping the matchmaking potential 
around GVCs between regional smart specialisation priorities, identifying some pilot 
examples of interregional value chains, key stakeholders, available equipment and 
facilities and relevant actors/skills in smart specialisation areas and applying the 
methodology described above with a view to identifying opportunities for matching of 
national and regional cluster organisations in identified value chains of smart 
specialisation areas. 
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